Formycon presents clinical data on ustekinumab biosimilar FYB202

20 February 2025

Formycon’s (FSE: FYB) shares edged up 2.4% to 30.60 euros as it revealed it is presenting an overview of the comparative data of the ustekinumab biosimilar FYB202 at this year's Congress of the European Crohn's and Colitis Organization (ECCO), now taking place in Berlin, Germany.

The poster presentation summarizes the clinical Phase I and Phase III study results and is complemented by advanced analytical laboratory data demonstrating the comparability of FYB202 with the reference prod///uct Johnson & Johnson’s (NYSE: JNJ) Stelara (ustekinumab).

The news comes just days after the German biosimilars developer announced it had decided to prematurely terminate the Phase III trial (Lotus) for its biosimilar candidate FYB206, referencing Merck & Co’s (NYSE: MRK) mega blockbuster Keytruda (pembrolizumab), saying that continuation of the study is no longer necessary for the development and approval of FYB206 in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK